{"id":"switching-to-nph-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting insulin formulation created by complexing insulin with protamine, which slows its absorption and extends its duration of action to 10-16 hours. It works by mimicking the body's natural basal insulin secretion, allowing sustained glucose control between meals and overnight. When patients switch to NPH insulin, they transition from other insulin regimens to achieve improved glycemic control with this specific pharmacokinetic profile.","oneSentence":"NPH insulin is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:26.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05614089","phase":"PHASE4","title":"Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","status":"COMPLETED","sponsor":"Jing Luo","startDate":"2023-03-15","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes","enrollment":400},{"nctId":"NCT06999551","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.","status":"NOT_YET_RECRUITING","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2025-07-01","conditions":"Diabetes Mellitus","enrollment":60},{"nctId":"NCT01854723","phase":"PHASE4","title":"Comparison Study of Insulin Glargine and NPH Insulin","status":"WITHDRAWN","sponsor":"Providence Health & Services","startDate":"2013-04","conditions":"Diabetes","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":74,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humulin N","Novolin N","Novolin NPH","NPH Iletin II","Isophane insulin"],"phase":"marketed","status":"active","brandName":"Switching to NPH insulin","genericName":"Switching to NPH insulin","companyName":"Providence Health & Services","companyId":"providence-health-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NPH insulin is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}